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Abstract
Background: Case-control studies typically exclude fatal endpoints from the case set, which we hypothesize will
substantially underestimate risk if survival is genotype-dependent. The loss of fatal cases is particularly nontrivial for
studies of coronary heart disease (CHD) because of significantly reduced survival (34% one-year fatality following a
coronary attack). A case in point is the KIF6 Trp719Arg polymorphism (rs20455). Whereas six prospective studies
have shown that carriers of the KIF6 Trp719Arg risk allele have 20% to 50% greater CHD risk than non-carriers,
several cross-sectional case-control studies failed to show that carrier status is related to CHD. Computer
simulations were therefore employed to assess the impact of the loss of fatal events on gene associations in cross-
sectional case-control studies, using KIF6 Trp719Arg as an example.
Results: Ten replicates of 1,000,000 observations each were generated reflecting Canadian demographics.
Cardiovascular disease (CVD) risks were assigned by the Framingham equation and events distributed among KIF6
Trp719Arg genotypes according to published prospective studies. Logistic regression analysis was used to estimate
odds ratios between KIF6 genotypes. Results were examined for 33%, 41.5%, and 50% fatality rates for incident
CVD.
In the absence of any difference in percent fatalities between genotypes, the odds ratios (carriers vs. noncarriers)
were unaffected by survival bias, otherwise the odds ratios were increasingly attenuated as the disparity between
fatality rates increased between genotypes. Additional simulations demonstrated that statin usage, shown in four
clinical trials to substantially reduce the excess CHD risk in the KIF6 719Arg variant, should also attenuate the KIF6
719Arg odds ratio in case-control studies.
Conclusions: These computer simulations show that exclusions of prior CHD fatalities attenuate odds ratios of
case-control studies in proportion to the difference in the percent fatalities between genotypes. Disproportionate
CHD survival for KIF6 Trip719Arg carriers is suggested by their 50% greater risk for recurrent myocardial infarction.
This, and the attenuation of KIF6 719Arg carrier risk with statin use, may explain the genotype’s weak association
with CHD in cross-sectional case-control studies. The results may be relevant to the underestimation of risk in
cross-sectional case-control studies of other genetic CHD-risk factors affecting survival.
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Case-control comparisons are more commonly
employed for assessing gene associations than prospec-
tive cohort studies [1,2]. Their popularity arises from
two important considerations: 1) statistical power is
often limited by the number of cases, and 2) genetic
investigations require no consideration of the sequence
of cause and effect. In addition to their being cost-
effective, case-control studies may be the only reasonable
approach to study rare diseases [3]. Discussions of the
advantages and disadvantages of case-control studies in
the context of genetic studies, and the advantages of
prospective cohort studies, have been discussed in several
reviews [2,4].
Selection bias refers to subject composition affecting
genotype-phenotype associations. For example, non-
representative sample of the target population can affect
the generalizability of genetic association studies, even if
the biases do not differ between genotypes. More impor-
tantly with respect to genetic studies are sampling biases
that distort genotype-phenotype associations. Such dis-
tortions may be less likely to occur in prospective
cohort studies than case-control studies [2].
The potential for selection bias is an important limitation
of cross-sectional case-control comparisons. Prospective
studies (e.g., prospective cohorts and nested control
designs) can avoid selection biases, including selection bias
due to case fatalities, which can be substantial. For exam-
ple, the American Heart Association reported that approxi-
mately 34% of those who experience a coronary attack in a
given year die from it, as do 15% of those experiencing
myocardial infarctions [5]. Thirty-six percent of men and
47% of women die within 5 years of their first myocardial
infarction [5]. Prior history of myocardial infarction
increases the risk for subsequent sudden death by four- to
six-fold [5]. Depending on sex and clinical outcome, those
who survive the acute stage of a myocardial infarction have
1.5- to 15-fold increased risk of illness and death vis-à-vis
the general population [5]. These fatal events will be
included among cases in prospective study designs, but
missing in cross-sectional case-control comparisons.
A case in point is the kinesin-like protein 6 (KIF6)
Trp719Arg polymorphism (rs20455). Table 1 summarizes
the findings of seven prospective studies of the KIF6
Trp719Arg polymorphism in relation to CHD, including
four in the absence of statin use: 1) the nested case-control
comparison of placebo-treated West of Scotland Coronary
Prevention Study (WOSCOPS) patients [6]; 2) the pro-
spective follow-up of the placebo-treated patients in the
Cholesterol and Recurrent Events (CARE) secondary pre-
vention trial [7]; 3) the prospective follow-up of placebo-
treated PROSPER (PROspective Study of Pravastatin in
the Elderly at Risk) elderly patients with pre-existing
vascular disease [8]; and 4) prospective follow-up of the
Heart Protection Study (HPS) [9]. Taken together, WOS-
COPS and CARE showed prospectively that KIF6 719Arg
increased primary and secondary CHD risk by about 50%
in statin-untreated subjects with moderate to high LDL-
cholesterol. This risk estimate is somewhat greater than
the 28% increased risk for fatal and nonfatal cardiovascular
events for KIF6 719Arg carriers (P = 0.07, where carriers
have at least one copy of the risk allele) in PROSPER [8],
and the 17% increased risk for major coronary events in
HPS (P = 0.2) [9]. Statin use has been shown to mitigate
or eliminate the higher CHD risk of KIF6 719Arg carriers
[6,8,10], and three other prospective studies of Table 1 did
not control for statin use [11-14]. These include the
Women’s Health Study (WHS) [11], the Cardiovascular
Health Study (CHS) [12], and the Atherosclerosis Risk in
Communities study (ARIC) [13,14]. Nevertheless, all three
assign greater CHD risk to KIF6 719Arg carriers [11,12] or
homozygotes [13,14].
Recently, Assimes et al. reported that KIF6 719Arg
carriers showed no greater odds for coronary artery
disease when 17,000 cases were compared to 39,369
controls of European descent in a meta-analysis of
19 case-control studies [15]. The studies included myo-
cardial infarctions, and clinically significant coronary
atherosclerosis without myocardial infarction including
ischemia, unstable angina, and revascularization proce-
dures. The meta-analyses included studies whose sub-
jects were enrolled weeks, months and years after their
initial CAD event. There was no adjustment for statin
use or traditional risk factors other than age and
sex. The absence of a significant risk increase for
KIF6719Arg carriers was reported for both the total
sample and for early onset cases and matched controls,
and appeared consistent across individual studies.
This report presents computer simulations to assess
the impact of survival bias and effect measure modification
by statin use on the detection of genotype-phenotype
association in case-control studies. There is a 50% greater
risk for recurrent myocardial infarction in carriers of the
KIF6 719Arg variant, which suggests poorer survival for
this genotype [6]. These simulations focus on the KIF6
Trp719Arg polymorphism due to its having shown
strong, repeated associations with CHD prospectively
[6-8,11-14], however, survival bias and effect-measure
modification may also cause difficulties in identifying and
replicating other CHD-related genetic polymorphisms in
cross-sectional case control-studies.
Results
Survival bias
Figure 1 demonstrates the potential bias arising from
subject exclusion due to prior fatalities. Results are
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prior fatalities among incident CVDs. That is, 50%
exclusion means that for the population from which the
cases are drawn, 50% of the potential cases died and are
not available to be chosen as cases in a cross-sectional
comparison. The X-axis represents the difference in
fatalities between genotypes. That is, zero on the X-axis
indicates that even though KIF6 719Arg carriers are
more likely to have a myocardial infarction than is a
noncarrier, given that a myocardial infarction has
occurred, a KIF6 719Arg carrier is no more likely to die
from the event than is a noncarrier. In the absence of
any difference in percent fatalities between genotypes,
odds ratios of 1.55 (for 50% increased risk for the KIF6
719Arg carriers) and 1.29 (for 25% increased risk for
carriers) were obtained regardless of the portion that
survived, otherwise the odds ratios were increasingly
attenuated as the disparity in fatality rates between gen-
otypes increased. For example, assuming a 25%
increased risk for KIF6 719Agr carriers vs. noncarriers
and an overall fatality rate of 41.5%, the odds ratio was
reduced to 1.18, 1.11, and 1.08, respectively, for 10%,
20%, and 25% differences in %fatality between carriers
and noncarriers. The attenuation increases substantially
with the fatality rate when the rate was disproportionate
between genotypes (e.g., the odds ratios at 33%, 41.5%
and 50% showed no difference when there was no dif-
ference in %fatalities between carriers and noncarriers,
showed moderate differences when there was a 10% dif-
ference in %fatalities between carriers and noncarriers,
and large differences when there was a 25% difference
in %fatalities between carriers and noncarriers.
Bias due to the differential effect of statin treatment by
KIF6 719Arg carrier status
The analyses of Figure 2, assume that KIF6 719Arg
increased CVD risks by 50% (consistent with WOS-
COPS and CARE trials [6]) and by 25% (consistent with
ARIC and WHS [11,14]) in nonstatin users, and by 0%
in statin users. Without statin use, the KIF6 719Arg car-
rier vs. noncarrier odds ratios were 1.55 and 1.27,
respectively. The odds ratios decline with greater statin
use, i.e., at 50% and 25% increased risk for KIF6 719Arg
carriers vs. noncarriers, the odds ratios declined to 1.43
Table 1 Studies of KIF6 and CHD or CVD risk
Events/Total Risk allele frequency Hazard ratios
Arg/Arg Arg/Trp Trp/Trp Arg/Arg Arg/Trp Arg carriers
CARE[6]
1 16/155 82/636 44/542 35.5 1.33 (P = 0.33) 1.54 (P = 0.02) 1.50 (P = 0.03)
WOSCOPS[6]
2 35/94 137/341 104/360 33.3 1.48 (P = 0.11) 1.56 (P = 0.006) 1.55 (P = 0.005)
ARIC [13]
3 144/1252 474/4363 382/3926 36.0 1.22 (P = 0.03) 1.12 (P = 0.09) (P = 0.02)
8
Woman’s Health Study [11]
4 95/3249 349/11831 256/10203 36.3 1.25 (P = 0.09) 1.23 (P = 0.02) 1.24 (P = 0.01)
PROSPER with vascular disease [8]
5 25/159 119/573 83/514 35.8 1.02 (P = 0.95) 1.36 (P = 0.03) 1.28 (P = 0.07)
PROSPER without vascular disease [8]
5 13/209 70/759 69/668 36.0 0.64 (P = 0.15) 0.87 (P = 0.43) 0.82 (P = 0.23)
Heart Protection Study [9]
6 1.17 (P = 0.2)
CHS-White [12]
7 1.29 (P = 0.005)
CHS-Black [12]
7 4.14 (P = 0.08)
1 Secondary prevention of fatal and nonfatal myocardial infarction;
2Primary prevention of CHD death, nonfatal myocardial infarction, revascularization;
3 Primary
definite, probable and silent myocardial infarctions, definite fatal CHD death, or coronary revascularization;
4Primary myocardial infarction or stroke, coronary
revascularization, cardiovascular death;
5Primary or secondary prevention of CHD death, myocardial infarction, or revascularization;
6Major coronary events;
7Primary or secondary myocardial infarction (definite or probable nonfatal and definite fatal).
8Additive model.
Figure 1 Simulated effects of genotype-differences in fatalities
on the odds ratio for CVD in KIF6 719Arg carriers vs.
noncarriers. KIF6 719Arg carriers are assumed to represent 59% of
the population and to increase CVD risk by 50% (consistent with
WOSCOPS and CARE trials [6]) and by 25% (consistent with ARIC
and WHS [11,13]) relative to noncarriers. X-axis represents the
percent difference in fatality between carriers and noncarriers of the
KIF6 allele (see methods).
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1.33 and 1.17 with 40% statin use, respectively, and
declined to 1.21 and 1.12 for 60% statin use, respec-
t i v e l y .B y9 0 %s t a t i nu s et h eo d d sr a t i of o rC V Dw a s
essentially one for KIF6 719Arg carriers compared with
noncarriers.
A second important result of Figure 2 is that standard
statistical adjustment for statin use did not correct for
the drug’s attenuation of CVD risk in KIF6 719Arg car-
riers. Identical curves were obtained whether or not sta-
tin use was included in the logistic regression model as
a covariate. This is because statin interacts with the
KIF6 719Arg carriers in determining CVD risk, rather
than contributing additively to the log odds for CVD.
Whereas Figure 2 assumes that all of the excess risk
associated with KIF6 719Arg carrier status is eliminated
by statin use, Figure 3 examines the effect of varying the
risk reduction associated with statin. Figure 3 suggests
that the odds reduction is proportional to the percen-
tage of the excess risk eliminated by statin use.
Discussion
In prospective cohort studies, genetic variants are identi-
cally recruited at baseline and ascertained for incident
diseases during follow-up using standardized diagnoses.
In case-control studies, spurious associations between
genotype and phenotype may arise when the study
design or subject participation leads to genotypic
differences between cases and controls that are unre-
lated to the etiology of the disease itself. Responder bias
is potentially greater for case-control than cohort studies
because recruitment or response may differ between
cases and controls. For example, it is not uncommon
for control subjects to be derived from geographical,
occupational, or environmental sources that differ from
those for cases [16]. Cases may also be more motivated
to participate than controls in studies that are relevant
to the cases’ own health concerns. The general popula-
tion may not identify as strongly with the study goals as
do cases, and those that volunteer may be healthier than
the general population.
In their review of psychiatric case-control studies, Lee
et al. concluded, “Genetic studies achieved the poorest
ratings in reducing selection bias” [17]. They point out
that few case-control studies adequately describe partici-
pant recruitment, which limits their evaluation and
potential for replication. Genetic case-control studies
require very large samples sizes in order to identify
associations between SNP and disease at genome-wide
statistical significance, or to obtain precise estimates of
the SNPs phenotypic effect. This may require the inclu-
sion of case-control comparisons that are poorly
matched. For example, 10 of the 19 different case-control
Figure 2 Simulated effects of statin use on the odds ratio for
CHD in KIF6 719Arg carriers vs. noncarriers. Results are
presented where KIF6 719Arg carriers have 50% or 25% increased
risk of CHD compared with noncarriers if there is no statin use, and
0% increased risk of CHD compared with noncarriers if statins are
used. Odds ratios (vertical axis) are presented for increasing
percentage of statin use (horizontal axis).
Figure 3 Simulated effects of statin use on the odds ratio for
CHD in KIF6 719Arg carriers vs. noncarriers. for varying effects of
statin on KIF6 719Arg carriers risk. Results are presented where KIF6
719Arg carriers have 50% increased risk of CHD compared with
noncarriers if there is no statin use, and where statin use eliminates
20%, 40%, 60%, 80% and 100% of the excess risk associated with
KIF6 719Arg carrier status (Figure 2 assumed 100% of the excess risk
was eliminated by statin use). Odds ratios (vertical axis) are
presented for increasing percentage of statin use (horizontal axis).
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t w i c ea sm a n yf e m a l e si nt h ec o n t r o l st h a nt h et r e a t -
ment groups (including one comparison of exclusively
male cases vs. a control group of over 50% women)
[15]. This may not affect the analyses because effects
of KIF6 719Arg carrier are not known to associate
with either sex or age, however, CHD is strongly age
and sex dependent and the analyses does rely on the
adequacy of the statistical adjustment to correct for
their effect.
Survival bias
O u rc o m p u t e rs i m u l a t i o n ss h o wt h a ts u r v i v a lb i a s ,a
type of incidence-prevalence bias [18], can substantially
attenuate the underlying risk associated with genetic
polymorphisms in case-control studies. This occurs
when there is greater exclusion of cases in high-risk
genotypes due to reduced survival. For a fixed sample
size, the decline in the odds will correspond to a reduc-
tion in statistical significance, although even very small
risk reductions will remain statistically significant if the
sample size is sufficient. In contrast, prospective cohort
and nested control studies include all incident cases
during follow-up, including fatal cases. Others have dis-
cussed survival bias in non-genetic context, for example
with regards to the interpretation of trauma treatment
[19]. Although generally recognized in epidemiological
research, survival bias remains a largely unrecognized
problem of gene-disease associations in genetic cross-
sectional case-control studies.
Bias due to the differential effect of statin treatment by
KIF6 719Arg carrier status
In addition to survival bias, failure to account for statin
use may contribute to the weaker association between
KIF6 genotypes and CHD in case-control studies. Four
studies have thus far demonstrated that statins signifi-
cantly reduce CHD-risk in carriers of KIF6 719Arg,
whereas noncarriers derive less benefit from statins
[6,8,10]. This disparity in statin benefit will attenuate
the association between incident CHD and KIF6 719Arg
in studies that fail to exclude statin users. For example,
Figure 2 suggests a weaker association between the KIF6
719Arg and CHD in several studies included in the ana-
lyses by Assimes et al. [15] might be due, in part, to sta-
tin use among cases (e.g., case use of lipid lowering
drugs were reported for 74% in the WTCCC study [20],
66% in the German Myocardial Infarction Family Stu-
dies [20], 62% in the Heart Attack Risk in Puget Sound
Study [21], 35% in the Massachusetts General Hospital
Premature CAD Study [22]) in addition to survival
selection. The Ottawa Heart Genomics Study [23] also
found no difference in the KIF6 719Arg allele distribu-
tion between angiographically defined coronary artery
disease cases and community controls, which could be
due, in part, by high statin use (89%) among the cases,
in addition to survival selection. From the descriptions
provided, the portion of the statin users that were on
their medication prior to their myocardial infarction or
angiographically defined coronary artery disease cannot
be determined for Ottawa Heart Genomics Studies and
the various studies used by Assimes et al. The statin
usages cited above would include more aggressive lipid
interventions subsequent to the event, and post-incident
statin use may actually prevent the loss of KIF6 719Arg
carriers among cases.
The nonsignificance of the Ottawa Heart Genomics
Study may also reflect in part an effect of the KIF6 gen-
otypes on CHD that is independent of the extent of
atherosclerosis [23]. CHD risk reductions in statin-trea-
ted KIF6 719Arg carriers appear to occur too soon to be
attributable to reduced stenosis and may relate to
improved plaque stability [10]. Two studies, in fact,
show statins reduced CHD events in some individuals
experiencing little LDL-C lowering [8,10]. In this regard,
it is not surprising that two studies that designated
cases by angiography scores in Assimes et al.’sa n a l y s e s
showed no increased risk for KIF6 719Arg carriers
[24,25].
The potential effect-measure modification due to sta-
tin use is not limited to case-control studies. Three of
the prospective studies of Table 1 did not explicitly
exclude or control for statin use, which may have atte-
nuated or eliminated KIF6 719Arg’s true risk. The ARIC
study showed that homozygotes and heterozygotes of
the KIF6 719Arg risk allele had 22% and 12% greater
risk for incident CHD, respectively, when adjusted for
age and sex [13] (P = 0.05 for additive model). The CHS
13-year follow-up of 3,849 white men and women aged
65 years and older showed that KIF6 719Arg increased
the risk of incident myocardial infarction by 29% [12].
The WHS 12-year prospective follow-up of 26,274 initi-
ally healthy women ≥45 years showed that carriers of
the KIF6 719Arg had 34% greater risk for myocardial
infarction and 24% greater risk for total cardiovascular
events (cardiovascular death, myocardial infarction,
ischemic stroke, and revascularization procedures) than
noncarriers [11].
Historically, candidate genes have been more prone to
false positives than GWA studies [26], presumably
because little attention was given to the total number of
candidate SNPs targeted in these initial studies, and not
because there were biological rationales for SNP selec-
tion. This phenomenon is not relevant to KIF6 719Arg
results that have been shown to be significant in 6 out
of 9 study groups, and positive in 8 out of 9 study
groups (Table 1), i.e., if the initial discovery of increased
risk for KIF6 719Arg had been a false positive, then we
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would show significantly increased risk. Historically,
poor reproducibility was also true for GWAS discoveries
that failed to adequately correct for multiple hypothesis
testing. Of course, GWAs can also be applied to pro-
spective studies.
The attenuating effects of statin on KIF6 719Arg’s
association with CHD are akin to the attenuating effects
of folate on MTHFR (5,10-Methylenetetrahydrofolate)’s
association with CHD. Those having the 677C_T
(Ala222Val) substitution in the MTHFR gene have
lower MTHFR and higher plasma homocysteine levels
[27-29]. Whereas some studies report an association
between MTHFR and CHD or myocardial infarction
[30-34], others do not [29,35], which has been attributed
to an amelioration of homocysteine risk by folate and B
vitamins. Higher folate intake has also been proposed to
explain why the 677C®T (Ala222Val) polymorphism of
MTHFR predicts CHD in the Middle East and Asia
w h e r ef o l a t ei n t a k ei sl o w ,b u tn o ti nE u r o p e ,N o r t h
America, or Australia where folate intake is high [36].
A cautionary note of treatment associated shrinkage of
risk effects was addressed statistically by Tobin et al. in
context of anti-hypertensive therapy and provides
further support of the potential underestimation of
genetic associations when unadjusted for treatment [37].
Limitations
Our simulated results should be interpreted with cau-
tion. The parameters we set in our simulations to illus-
trate the potential impact of differential fatality and
statin use on the outcome of a case-control genetic
association study may be less extreme in different set-
tings, for example there may be a smaller attenuating
effect of statin on CVD risk in KIF6 719Arg carriers.
Although disproportionate CHD survival for KIF6 Tri-
p719Arg carriers is suggested by their 50% greater risk
for recurrent myocardial infarction, we currently do not
have direct evidence for a difference in fatality following
cardiovascular events between 719Arg carriers and non-
carriers, nor are we aware of other genetic variants that
are associated with increased fatality after cardiovascular
event. The moderate effect of the KIF6 719Arg variant
on the risk of cardiovascular events may suggest that
differences in fatality following cardiovascular events are
small. This could explain a lack of significant deviation
from Hardy-Weinberg equilibrium expectation for the
KIF6 Trp719Arg polymorphism in individuals 65 years
or older [12], although the statistical power to detect
such differences may be lacking. The prevalence of sta-
tin use among those eligible to become cases, prior to
their index event may be modest as well. For example,
5% to 15% statin use occurring in populations where
cases are drawn in case-control studies of cardiovascular
disease, would have a negligible effect on the risk esti-
mate (Figure 2). Finally, our simulations considered each
of these parameters independently; however, these fac-
tors may interact, in aggregate, to result in shrinkage of
higher risks of coronary events.
Conclusions
In summary, our simulations illustrate several potential
pit-falls to genetic case-control studies of disease risk.
Discrepancies between prospective and case-control stu-
dies are not uncommon, with the hormone replacement
therapy being one of the better-known examples.
Whereas prior case-control studies of hormone replace-
ment therapy suggested 30% to 50% reductions in CHD
risk and little increased risk for stroke [38], its use in the
Women’s Health Initiative was terminated early due to
significant increase stroke risk with little apparent reduc-
tion in CHD risk [39]. It seems unlikely that the signifi-
cant increases in CHD risk in KIF6 719Arg carriers is
s i m p l yac h a n c eo c c u r r e n c e( T a b l e1 ) ,a n dt h a tc a r e f u l
consideration as to why prospective and case-control
designs may lead to differing results is warranted.
Prospective cohort studies may lack the cost savings
for studying specific disease outcomes and generally
require extended elapsed time to complete, but likely
provide less biased results. Cohort studies also produce
archival genetic material that can be interrogated afresh
to test and verify emerging hypotheses. When based
upon case-control studies, where inclusion depends
u p o nt h eg e n o t y p ea f f e c t i n gs u r v i v a l ,t h es m a l lt om o d -
erate CHD risks heretofore attributed to most poly-
morphisms may be underestimates of substantially
greater actual risk. Further, other genetic variants that
are associated with both disease risk and drug response
may have been missed in GWA studies where underly-
i n gd r u gu s ea m o n gh i g h - r i s kc a s e si so f t e nu n k n o w n
and could be extensive. These concerns regarding
genetic associations in cross-sectional case-control study
design are in addition to other potential caveats dis-
cussed by others [40-42]. The apparent “missing herit-
ability” of genome wide association studies is well
recognized (i.e., the heritability difference as estimated
from family and twin studies versus GWA studies [43]).
In advance of potentially uncovering rare variant asso-
ciations through genome sequencing studies, whose
cost-effectiveness will be delayed for years [44], the sur-
vival and treatment biases noted here should be consid-
ered as potential factors in the reduction in effect size
of associated risk variants of genome-wide association
studies [45,46].
Methods
Simulations were performed using the uniform random
number generator and logistic regression statistical
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assess the impact of survival bias, ten replicates of
1,000,000 observations each were generated based on
the age and sex distribution of Canadians from the 2006
census [47]. These were assigned CVD risk from the
Framingham Health Study based on their sex and
cumulative disease incidence between age 40 and their
current age [48]. CVD risk was examined because
ischemic stroke was included among endpoints in the
WHS [11]. Fifty nine percent of the sample was ran-
domly designated as KIF6 719Arg carriers in accordance
with published reports [6-8,11-13] and their CVD risk
increased by 50% (consistent with WOSCOPS and
CARE trials [6]) or by 25% (consistent with ARIC and
WHS [11,14]) relative to noncarriers. Events assigned by
comparing an individual’s CVD risk to random number
generated from the uniform distribution, from which we
excluded randomly selected cases in accordance with
carrier-specific survival rates. The difference in survival
rate between KIF6 719Arg carriers and noncarriers was
specified to keep the overall rate constant (e.g., by set-
ting the fatality rate to 55% in carriers and 43% in non-
carriers, the overall event rate remains 50% in carriers
and noncarriers combined, i.e., 55%*.59 + 43%*.41 =
50%, and there is 25% reduction in the event rate for
carriers vs. noncarriers, i.e., 43 fatalities per 100 events
is 25% less than 55 fatalities per 100 events). Simulated
data were then analyzed by logistic regression analyses
with CVD as the dependent variable, and age, sex, and
KIF6 719Arg carrier status as the independent variables.
In these simulations, the particular population demo-
g r a p h i ca f f e c t so nt h ed i s e a s ei n c i d e n c eh a sl i t t l ea f f e c t
on the selection bias (verified by modest changes in the
simulation, results not displayed). The Canadian popula-
tion was chosen to address the potential affects of survi-
val bias for a particular Canadian-based report that
failed to demonstrate statistical significance [23]. With
95% confidence, ten replicates of 1,000,000 observations
were found to estimate the odds ratio within ±0.02.
To assess the bias due to the differential effect of sta-
tin treatment by KIF6 719Arg carrier status, ten repli-
cates of 1,000,000 observations were again generated
based on the age and sex distribution of Canadians,
assigned CVD risk using the Framingham Health Study
[47], and 59% of the sample randomly designated as
KIF6 719Arg carriers. Statin users were chosen at ran-
dom for 0%, 10%, 20%, ... 90% of the sample. The simu-
lated data were again analyzed by logistic regression
analyses with CVD as the dependent variable, and age,
sex, and KIF6 719Arg carrier status as the independent
variables. We also included statin use as an independent
variable to assess whether traditional statistical adjust-
ment corrects for statin use.
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